Literature DB >> 3113974

Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses.

P Girard, R Cohen, G Sassolas, C Harthe, P Cabrera, J P Boissel.   

Abstract

Three ranges of doses of growth hormone releasing factor (2.5-80 micrograms, 80-320 micrograms and 75-600 micrograms) were intravenously administered to healthy young volunteers in three double blind studies. Serum circulating GRF levels were determined by radioimmunoassay. Experimental concentration curves were fitted, using the extended least squares method, to a biexponential model for the structural model and power function for the variance model. The power variance model, compared to the constant variance model greatly reduced the coefficient of variation of the biexponential parameters. The power of the variance model was estimated to be 1.95. The distribution half-life was 6.6 min and the elimination half-life was 39.0 min (harmonic means). Total clearance was 0.12 +/- 0.01 microgram/l/min. No difference between these parameters was found for the various doses. GRF kinetics was linear established in the range 10 to 600 micrograms which means that elimination was not altered by the increased doses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3113974     DOI: 10.1007/bf00637679

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men.

Authors:  G Sassolas; J Garry; R Cohen; H Bastuji; E Vermeulen; P Cabrera; B Roussel; M Jouvet
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

2.  Clinical studies with human growth hormone releasing factor in normal adults and patients.

Authors:  G Sassolas; S Biot-Laporte; R Cohen; P Chatelain; J P Boissel; S Ferry; J A Chayvialle; P Dupin; P Garry; B Claustrat
Journal:  Peptides       Date:  1986       Impact factor: 3.750

3.  Synthetic human growth hormone releasing factor (h-GRF-I-44-NH2) dose response effect on growth hormone and prolactin secretion in healthy adult men.

Authors:  J P Boissel; R Cohen; S Biot-Laporte; B Claustrat; H Renard; M Olivier; G Sassolas
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

5.  Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

Authors:  L A Frohman; J L Thominet; C B Webb; M L Vance; H Uderman; J Rivier; W Vale; M O Thorner
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

6.  Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor.

Authors:  N Ling; F Esch; P Böhlen; P Brazeau; W B Wehrenberg; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

7.  Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.

Authors:  M O Thorner; J Rivier; J Spiess; J L Borges; M L Vance; S R Bloom; A D Rogol; M J Cronin; D L Kaiser; W S Evans; J D Webster; R M MacLeod; W Vale
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

8.  [Acromegaly, clinical expression of the production of growth hormone releasing factor in pancreatic tumors].

Authors:  G Sassolas; J A Chayvialle; C Partensky; G Berger; J Trouillas; F Berger; B Claustrat; R Cohen; C Girod; R Guillemin
Journal:  Ann Endocrinol (Paris)       Date:  1983       Impact factor: 2.478

9.  Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRH1-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men.

Authors:  G Sassolas; P Chatelain; R Cohen; J P Boissel; S Laporte; J Galleyrand; B Claustrat; A Elmcharfi; J A Chayvialle; H Cohen
Journal:  J Clin Endocrinol Metab       Date:  1984-10       Impact factor: 5.958

10.  Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women.

Authors:  M C Gelato; O H Pescovitz; F Cassorla; D L Loriaux; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

View more
  1 in total

1.  pNET co-secreting GHRH and calcitonin: ex vivo hormonal studies in human pituitary cells.

Authors:  Taiba Zornitzki; Hadara Rubinfeld; Lyudmila Lysyy; Tal Schiller; Véronique Raverot; Ilan Shimon; Hilla Knobler
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-02-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.